top of page
News & Events
Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells
February 16th, 2021
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
January 13th, 2021
Watch a replay of the Cell Therapy panel at the 10th Annual LifeSci Partners Corporate Access Event, featuring our CEO Dr. Daniel Teper
January 7th, 2021
Watch a replay of Cytovia's recent fireside chat at the RBC Capital Markets Healthcare Conference, featuring CEO Dr. Daniel Teper and CSO Dr. Wei Li
December 16th, 2020
Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors
December 8th, 2020
Watch Cytovia's recent presentation at the Jefferies London Healthcare Conference, featuring CEO Daniel Teper and CSO Wei Li
November 23rd, 2020
Cytovia Therapeutics to Present at Jefferies Virtual London Healthcare Conference
November 12th, 2020
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
October 8th, 2020
Watch Cytovia's recent webinar at the Jefferies Cell Therapy Virtual Summit, featuring CEO Dr. Daniel Teper and CSO Dr. Wei Lu
October 7th, 2020
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020
September 29th, 2020
Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer
August 25th, 2020
Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic
August 12th, 2020
Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors
August 3rd, 2020
June 24th, 2020
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer
June 3rd, 2020
Cytovia CEO Daniel Teper Featured on MSQ Webinar Series
March 24th, 2020
Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research
March 18th, 2020
Webcast: BIO CEO & Investor Conference
February 12th, 2020
Cytovia CEO interviewed by Proactive
February 11th, 2020
Cytovia's CAR NK Alliance With NYSCF, UCSF Aims to Overcome Negative Side Effects of CAR T Drugs
February 3rd, 2020
Cytovia Therapeutics to present at BIO CEO & Investor Conference
February 3rd, 2020
Cytovia Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics
January 9th, 2020
Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy
January 6th, 2020
Cytovia Therapeutics, Inc. and STC Biologics, Inc. enter into a partnership to develop and manufacture NK cell engager multi-specific antibodies
January 2nd, 2020
Cytovia CEO Dr. Daniel Teper to speak at East/West Conference
December 29th, 2019
October 28th, 2019
Cytovia Therapeutics to Present at 2019 Bio Investor Forum
October 21st, 2019
bottom of page